Humacyte, Inc. Capital Expenditures
Humacyte, Inc. (HUMA) reported Capital Expenditures of $279.00 thousand for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-12.
Financial Statements › Cash Flow › Investing Activities
us-gaap:PaymentsToAcquirePropertyPlantAndEquipment · last filed 2026-08-12
- Humacyte, Inc. payments to acquire property, plant, and equipment for the quarter ending 2026-06-30 was $104.00K, a 81.69% decline year-over-year.
- Humacyte, Inc. payments to acquire property, plant, and equipment for the quarter ending 2026-03-31 was $175.00K, a 23.25% decline year-over-year.
- Humacyte, Inc. payments to acquire property, plant, and equipment for the quarter ending 2025-12-31 was $39.00K, a 38.10% decline year-over-year.
- Humacyte, Inc. payments to acquire property, plant, and equipment for the quarter ending 2025-09-30 was $49.00K, a 94.75% decline year-over-year.
- Humacyte, Inc. payments to acquire property, plant, and equipment for fiscal 2025 was $884.00K, a 43.77% decline from fiscal 2024.
- Humacyte, Inc. payments to acquire property, plant, and equipment for fiscal 2024 was $1.57M, a 31.05% decline from fiscal 2023.
- Humacyte, Inc. payments to acquire property, plant, and equipment for fiscal 2023 was $2.28M, a 117.56% increase from fiscal 2022.
- Humacyte, Inc. payments to acquire property, plant, and equipment for fiscal 2022 was $1.05M, a 376.36% increase from fiscal 2021.
| Period end | Payments to Acquire Property, Plant, and Equipment 3 month | Payments to Acquire Property, Plant, and Equipment 6 month | Payments to Acquire Property, Plant, and Equipment 9 month | Payments to Acquire Property, Plant, and Equipment 12 month |
|---|---|---|---|---|
| 2026-06-30 | $104.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-12 | $279.00K 10-Q · filed 2026-08-12 | $318.00K derived: sum of 3 quarters · filed 2026-08-12 | $367.00K derived: sum of 4 quarters · filed 2026-08-12 |
| 2026-03-31 | $175.00K 10-Q · filed 2026-05-13 | $214.00K derived: sum of 2 quarters · filed 2026-05-13 | $263.00K derived: sum of 3 quarters · filed 2026-05-13 | $831.00K derived: sum of 4 quarters · filed 2026-08-12 |
| 2025-12-31 | $39.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-27 | $88.00K derived: sum of 2 quarters · filed 2026-03-27 | $656.00K derived: sum of 3 quarters · filed 2026-08-12 | $884.00K 10-K · filed 2026-03-27 |
| 2025-09-30 | $49.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-12 | $617.00K derived: sum of 2 quarters · filed 2026-08-12 | $845.00K 10-Q · filed 2025-11-12 | $908.00K derived: sum of 4 quarters · filed 2026-08-12 |
| 2025-06-30 | $568.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-12 | $796.00K 10-Q · filed 2026-08-12 | $859.00K derived: sum of 3 quarters · filed 2026-08-12 | $1.79M derived: sum of 4 quarters · filed 2026-08-12 |
| 2025-03-31 | $228.00K 10-Q · filed 2026-05-13 | $291.00K derived: sum of 2 quarters · filed 2026-05-13 | $1.23M derived: sum of 3 quarters · filed 2026-05-13 | $1.41M derived: sum of 4 quarters · filed 2026-05-13 |
| 2024-12-31 | $63.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-27 | $997.00K derived: sum of 2 quarters · filed 2026-03-27 | $1.18M derived: sum of 3 quarters · filed 2026-03-27 | $1.57M 10-K · filed 2026-03-27 |
| 2024-09-30 | $934.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-12 | $1.12M derived: sum of 2 quarters · filed 2025-11-12 | $1.51M 10-Q · filed 2025-11-12 | $1.66M derived: sum of 4 quarters · filed 2025-11-12 |
| 2024-06-30 | $184.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-11 | $575.00K 10-Q · filed 2025-08-11 | $725.00K derived: sum of 3 quarters · filed 2025-08-11 | $1.22M derived: sum of 4 quarters · filed 2025-08-11 |
| 2024-03-31 | $391.00K 10-Q · filed 2025-05-13 | $541.00K derived: sum of 2 quarters · filed 2025-05-13 | $1.03M derived: sum of 3 quarters · filed 2025-05-13 | $1.52M derived: sum of 4 quarters · filed 2025-05-13 |
| 2023-12-31 | $150.00K derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-31 | $643.00K derived: sum of 2 quarters · filed 2025-03-31 | $1.13M derived: sum of 3 quarters · filed 2025-03-31 | $2.28M 10-K · filed 2025-03-31 |
| 2023-09-30 | $493.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-08 | $978.00K derived: sum of 2 quarters · filed 2024-11-08 | $2.13M 10-Q · filed 2024-11-08 | $2.81M derived: sum of 4 quarters · filed 2024-11-08 |
| 2023-06-30 | $485.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-13 | $1.64M 10-Q · filed 2024-08-13 | $2.32M derived: sum of 3 quarters · filed 2024-08-13 | $2.53M derived: sum of 4 quarters · filed 2024-08-13 |
| 2023-03-31 | $1.15M 10-Q · filed 2024-05-13 | $1.83M derived: sum of 2 quarters · filed 2024-05-13 | $2.04M derived: sum of 3 quarters · filed 2024-05-13 | $2.18M derived: sum of 4 quarters · filed 2024-05-13 |
| 2022-12-31 | $681.00K derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-28 | $892.00K derived: sum of 2 quarters · filed 2024-03-28 | $1.03M derived: sum of 3 quarters · filed 2024-03-28 | $1.05M 10-K · filed 2024-03-28 |
| 2022-09-30 | $211.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-09 | $345.00K derived: sum of 2 quarters · filed 2023-11-09 | $367.00K 10-Q · filed 2023-11-09 | $412.00K derived: sum of 4 quarters · filed 2023-11-09 |
| 2022-06-30 | $134.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-14 | $156.00K 10-Q · filed 2023-08-14 | $201.00K derived: sum of 3 quarters · filed 2023-08-14 | $284.00K derived: sum of 4 quarters · filed 2023-08-14 |
| 2022-03-31 | $22.00K 10-Q · filed 2023-05-12 | $67.00K derived: sum of 2 quarters · filed 2023-05-12 | $150.00K derived: sum of 3 quarters · filed 2023-05-12 | $213.00K derived: sum of 4 quarters · filed 2023-05-12 |
| 2021-12-31 | $45.00K derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-24 | $128.00K derived: sum of 2 quarters · filed 2023-03-24 | $191.00K derived: sum of 3 quarters · filed 2023-03-24 | $220.00K 10-K · filed 2023-03-24 |
| 2021-09-30 | $83.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-10 | $146.00K derived: sum of 2 quarters · filed 2022-11-10 | $175.00K 10-Q · filed 2022-11-10 | $188.00K derived: sum of 4 quarters · filed 2022-11-10 |
| 2021-06-30 | $63.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-12 | $92.00K 10-Q · filed 2022-08-12 | $105.00K derived: sum of 3 quarters · filed 2022-08-12 | |
| 2021-03-31 | $29.00K 10-Q · filed 2022-05-13 | $42.00K derived: sum of 2 quarters · filed 2022-05-13 | ||
| 2020-12-31 | $13.00K derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-29 | $318.00K 10-K · filed 2022-03-29 | ||
| 2020-09-30 | $305.00K 10-Q · filed 2021-11-15 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Outlook Therapeutics, Inc. (OTLK) | United States | $0.162B | -4.90 |
| Acumen Pharmaceuticals, Inc. (ABOS) | United States | $0.162B | -1.83 |
| Tenaya Therapeutics, Inc. (TNYA) | United States | $0.140B | -1.60 |
| Voyager Therapeutics, Inc. (VYGR) | United States | $0.173B | -1.99 |
| PRECISION BIOSCIENCES INC (DTIL) | United States | $0.175B | -3.95 |
| Caribou Biosciences, Inc. (CRBU) | United States | $0.134B | -1.79 |
| Armata Pharmaceuticals, Inc. (ARMP) | United States | $0.132B | |
| Neumora Therapeutics, Inc. (NMRA) | United States | $0.132B | -1.48 |
| enGene Therapeutics Inc. (ENGN) | $0.129B | -0.92 | |
| Coherus Oncology, Inc. (CHRS) | United States | $0.182B | -1.63 |